Core Viewpoint - The 2026 China Development Forum held in Beijing highlighted the commitment of multinational medical device companies to increase investment and deepen local cooperation in China, emphasizing the country's central role in the global medical device industry [3][18]. Group 1: High-Level Meetings - Prior to the forum, executives from multinational medical device companies engaged in intensive discussions to lay the groundwork for deeper cooperation in China [19]. - Chinese government officials, including the Minister of Commerce and a Vice Premier, met with leaders from major multinational pharmaceutical and medical device companies to address industry concerns and foster communication [19]. Group 2: Key Speeches from Multinational Executives - Executives from various multinational medical device companies shared their experiences and policy suggestions during the forum, expressing a strong commitment to grow alongside the Chinese market [20]. Group 3: Medtronic's Localization Strategy - Medtronic's CEO emphasized the company's "Localization 3.0" strategy, viewing China as a critical hub for high-quality medical technology development and global innovation [21]. - Medtronic plans to establish a "two-way bridge" to enhance connections between high-end medical device innovation in China and its global operations [21]. Group 4: Siemens Healthineers' Focus on Innovation - Siemens Healthineers' CEO highlighted China's role as a key driver of global healthcare innovation and praised government policies that promote equitable healthcare resource distribution [24]. - The company announced a significant investment of over 1 billion RMB in Shenzhen to establish a new high-end medical equipment R&D and manufacturing base, expected to be operational by 2027 [24]. Group 5: Roche's Commitment to Innovation - Roche's chairman celebrated the company's 100 years of service in China, acknowledging the government's strategic investments in building a leading innovation ecosystem [27]. - Roche suggested enhancing the commercial health insurance system to support sustainable development in the life sciences sector [27]. Group 6: Abbott's Contribution to Public Health - Abbott's CEO expressed pride in the company's role in improving public health in China since 1988, helping millions achieve better health through its global supply chain [29]. - The company's focus aligns with China's "Healthy China 2030" strategy, emphasizing the importance of strengthening primary healthcare services [29]. Group 7: Thermo Fisher Scientific's Investment in China - Thermo Fisher Scientific's CEO noted the company's 40-year commitment to China, recognizing the country's determination to drive high-quality development and open markets [30]. Group 8: Oculon’s Local Cooperation - Oculon's executives shared their global experiences in women's health and chronic disease management, emphasizing their commitment to deepening local cooperation in China [30]. Group 9: Overall Market Insights - The concentration of multinational executives at the forum reflects a strong recognition of China's healthcare market and its potential to influence global medical device industry dynamics [31]. - China's medical device market is becoming one of the largest globally, driven by an aging population and increasing health awareness, supported by the "Healthy China 2030" strategy [31].

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook compared to the market [3]. Core Insights - The report highlights the approval of the world's first invasive brain-computer interface (BCI) medical device for clinical application, marking a significant milestone in the industry [37]. - The implementation of DRG/DIP 3.0 is scheduled for January 2027, which is expected to optimize payment grouping rules and enhance the integration of DRG/DIP systems [38]. Market Performance - The pharmaceutical and biotechnology index fell by 2.77% this week, underperforming the CSI 300 index by 0.59 percentage points, ranking 8th in industry performance [14]. - Year-to-date, the pharmaceutical index has decreased by 2.9%, also lagging behind the CSI 300 index by 1.54 percentage points, ranking 20th [14]. Sub-industry Analysis - Among sub-industries, traditional Chinese medicine fell by 1.16%, biological products by 1.79%, chemical pharmaceuticals by 2.08%, medical devices by 4%, pharmaceutical commerce by 4.01%, and medical services by 4.32% [20]. - The medical device sector has shown the smallest decline year-to-date at -0.38%, while the chemical pharmaceutical sector has experienced the largest drop at -6.05% [20]. Notable Company Developments - Shanghai Ladder Medical Technology completed a strategic financing round of 500 million yuan, accelerating its clinical progress in brain-computer interface technology [34]. - Eli Lilly announced a plan to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for oral solid formulations [33].

Core Insights - Agilent has officially launched the NovoCyte Opteon Dx (spectral) flow cytometer in the Chinese market, marking its first clinically approved spectral flow cytometer [2] - The product features a 3-5 laser configuration and supports up to 73 detectors, utilizing full-spectrum acquisition and intelligent deconvolution technology to overcome traditional flow cytometry signal overlap limitations [3] Product Features and Applications - The NovoCyte Opteon Dx is designed to meet clinical high-throughput, high-precision, and high-compliance testing requirements, making it suitable for core clinical settings such as hospital laboratories and third-party medical labs [3] - It provides technical support for clinical needs including immunophenotyping, hematological diagnosis, and infection immune monitoring [3] Market Impact - The launch of Agilent's clinical spectral flow cytometer fills a gap in the domestic high-end spectral flow cytometry clinical equipment market, enriching the supply system of domestic high-end clinical flow cytometry products [3] - Agilent plans to continue advancing the product's technology and clinical applications, offering a one-stop solution from equipment delivery to technical support, thereby contributing to the high-quality development of precision medicine and in vitro diagnostics in China [3]

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook compared to the market [3]. Core Insights - The report highlights the approval of the world's first invasive brain-computer interface (BCI) medical device, marking a significant milestone in clinical applications [9][35]. - The implementation of DRG/DIP 3.0 is scheduled for January 2027, which is expected to optimize payment grouping rules and enhance the efficiency of healthcare funding [38]. Market Performance - The pharmaceutical index decreased by 2.77% this week, underperforming the CSI 300 index by 0.59 percentage points, ranking 8th in industry performance [14]. - Year-to-date, the pharmaceutical index has declined by 2.9%, also trailing the CSI 300 index by 1.54 percentage points, ranking 20th [14]. Sub-industry Analysis - Among sub-industries, traditional Chinese medicine fell by 1.16%, biological products by 1.79%, chemical pharmaceuticals by 2.08%, medical devices by 4%, pharmaceutical commerce by 4.01%, and medical services by 4.32% [20]. - The medical device sector has shown the smallest decline year-to-date at -0.38%, while the chemical pharmaceutical sector has experienced the largest drop at -6.05% [20][23]. Notable Company Developments - Shanghai Ladder Medical Technology completed a strategic financing round of 500 million yuan, enhancing its clinical trial progress in the brain-computer interface sector [34]. - Eli Lilly announced a plan to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for its oral GLP-1 receptor agonist [33]. Industry News and Policies - Jiangsu Province has released an action plan for the innovative development of the brain-computer interface industry, aiming for breakthroughs in technology and the establishment of industrial clusters by 2027 [33]. - The National Medical Insurance Administration has provided updates on the DRG/DIP 3.0 version, which will enhance the payment system for hospital services [38].

Group 1: Industry Overview - The overall attention from institutions has seen a rebound, particularly in the pharmaceutical, building materials, and communication sectors [1][2] - Weekly, the total number of companies surveyed in the A-share market decreased, remaining significantly lower than the same period in 2025, indicating a continued low level of survey activity [11][18] - Monthly, the total number of companies surveyed in February 2026 also fell compared to January, with a total of 451 surveys conducted, down from 1305 in February 2025 [18][20] Group 2: Sector-Specific Insights - The pharmaceutical, building materials, and communication sectors experienced an increase in survey activity compared to the previous week, with notable rises in the number of surveys conducted [11][17] - In the last month, the electronic, mechanical equipment, pharmaceutical, basic chemicals, and electric power equipment sectors received the highest attention from institutions [18][21] Group 3: Individual Company Focus - Companies such as Fuirjia, Guangli Technology, and Changlan Technology have garnered significant market attention, with Fuirjia receiving 18 surveys in the last month, indicating strong interest in its dental repair materials and digital equipment [31][32] - Aidi Te, involved in dental repair materials and digital equipment, has seen a favorable market demand, with two surveys conducted last week, reflecting growing industry demand driven by increased patient visits and rising per capita spending on dental care [30]

Core Viewpoint - Hyperfine has secured a $40 million loan from Horizon Technology Finance to support the commercialization of its portable MRI system, indicating a critical phase in the validation of a new technology path rather than just expansion [2]. Group 1: Technology Pathway - Hyperfine's core product, the Swoop portable MRI system, is an ultra-low field brain MRI device that has received FDA approval, focusing on higher accessibility rather than performance upgrades [2]. - The technology sacrifices some imaging capabilities to increase usability in scenarios where traditional MRI is not feasible, such as bedside use in ICUs and emergency rooms [3]. Group 2: Commercial Viability - The main challenge for Hyperfine is not the technical feasibility but whether the market size can support its business model, as the low-field MRI remains a supplementary device rather than a replacement for high-field MRI [5]. - The second-generation product utilizes AI algorithms to enhance image quality and scanning efficiency, but physical constraints of low-field MRI limit its application in high-demand scenarios like tumor diagnosis [5][6]. Group 3: Financing and Market Challenges - The recent financing indicates that while Hyperfine has a commercial foundation, it still relies on external funding for expansion, highlighting that a complete commercialization loop has not yet formed [8]. - The industry faces challenges where the speed of commercial rollout is expected to lag behind technological maturity due to various market factors [9]. Group 4: Implications for the Chinese Market - In China, portable MRI is in its early stages, with significant constraints on short-term market expansion due to unclear procurement logic, lack of payment systems, and the need for established usage habits among doctors [10][11]. - The realistic approach for market entry is to target high-demand scenarios like stroke and ICU settings for small-scale validation before broader expansion [12]. Group 5: Key Variables for Success - The success of Hyperfine's portable MRI as an independent market segment depends on three critical variables: the establishment of stable clinical usage paths, integration into insurance or sustainable payment mechanisms, and the emergence of large-scale procurement scenarios [14].

Core Insights - Dexcom's G7 product significantly reduces A1C levels and improves weight management in non-insulin-dependent type 2 diabetes patients, indicating a shift towards a larger market segment [2][8] - The company is transitioning from a focus on insulin-dependent patients to a broader base of type 2 diabetes patients who do not use insulin, which could redefine market potential [5][8] Group 1: Company Overview - Dexcom, established in 1999, is a pioneer in the commercialization of Continuous Glucose Monitoring (CGM) systems and remains a key player in the high-end CGM market [3] - The latest G7 product features smaller size, longer wear time (15 days), and enhanced data connectivity and algorithm capabilities, marking a shift from professional devices to consumer-grade wearables [6] Group 2: Market Dynamics - The CGM market is evolving from hospital-based monitoring to long-term management outside clinical settings, emphasizing data-driven diabetes management [6][10] - The focus is shifting from merely providing data to actively changing patient behavior and treatment outcomes, with tools like "Smart Basal" entering the algorithm-assisted treatment phase [10] Group 3: Implications for the Chinese Market - The growth potential in China lies outside hospitals, focusing on broader chronic disease management rather than just insulin-dependent patients [14] - Future competition will center on "data + services," moving beyond just sensor sales to include comprehensive management solutions [15][16] - Payment systems will be a critical factor in the adoption of CGM among non-insulin users, with successful expansion relying on a combination of payment frameworks and clinical evidence [19][20] Group 4: Future Growth Trajectory - The CGM industry is entering a "second growth curve," transitioning from replacing fingerstick blood tests to becoming a core tool in chronic disease management [21] - This next phase will be driven by expanding the patient population and realizing the value of data [22]

Core Viewpoint - The development logic of medical technology is shifting due to the upgrade of medical demand, iteration of engineering technology, and evolution of payment systems, with a focus on system-level solutions and industrial collaboration capabilities becoming central to the industry [2]. Event Overview - The Global MedTech Conference 2026 will be held on June 12, 2026, at the Zhongguancun Conference Center, featuring a core main forum alongside vertical forums in orthopedics, cardiovascular, neurotechnology, and medical aesthetics [4][5]. - The conference aims to connect engineering, clinical, enterprise, capital, and regulation from a macro and systematic industry perspective, focusing on innovation paths, product transformation, and industrial upgrades [3]. Awards and Recognition - The conference will include the 2026 Annual Medical Technology Innovation Awards, open for applications from medical technology companies, medical institutions, and related industry participants [5]. - Award-winning enterprises will gain visibility on the main stage of the conference and be included in annual industry content planning and long-term content systems, enhancing industry recognition and sustainable visibility [14]. Industry Interaction - The conference will feature premium exhibition spaces for sponsors to engage with high-quality decision-makers, facilitating product demonstrations and collaboration agreements [10]. - It will also provide opportunities for cross-institutional cooperation through specialized discussions and industry matchmaking activities [15]. Previous Conference Highlights - The second Global MedTech Conference showcased the release of the "2026 Global Medical Technology Innovation White Paper" and awarded 11 prizes in the 2025 Global Medical Technology Innovation Series [8][9]. - The event served as a significant platform for discussions on medical device innovation, medical-engineering transformation, and industry development [13].

Group 1 - The company Shenzhen Shangrong Medical Co., Ltd. has approved a guarantee for its wholly-owned subsidiary to apply for a credit limit of RMB 72 million from Industrial and Commercial Bank of China [1][2][21] - The credit limit consists of a non-specific credit limit of RMB 32 million and a specific credit limit of RMB 40 million, intended for trade financing and other banking services [1][5][21] - The guarantee is backed by the company and its major shareholder, Liang Guiqiu, who will provide personal unlimited joint liability [1][3][21] Group 2 - The guarantee is valid until February 28, 2030, and is intended for use in bank acceptance bills, letters of credit, and trade financing for medical equipment procurement [4][5][21] - The company has a total approved guarantee amount of RMB 736.6 million, which represents 18.99% of the total assets and 27.91% of the net assets as of December 31, 2024 [13] - The actual guarantee balance is RMB 211.47 million, accounting for 5.45% of total assets and 8.01% of net assets as of December 31, 2024 [13]

1. Reported Industry Investment Rating - No information provided 2. Core Viewpoints of the Report - The company's fundraising project is expected to meet expectations by the end of 2026 [24] - In 2026, the company will continue to implement the concept of high - quality, low - cost, and excellent service, stabilize and increase market share, introduce advanced technology and management concepts, accelerate the construction of intelligent factories, and actively cultivate and expand the international market [24] - The company will reduce inventory through market expansion and sales increase, and adjust the glass kiln overhaul time to reduce production capacity, and future impairment will have little impact on performance [26] - The decline in the company's revenue is related to the decline of domestic pharmaceutical enterprises and the need to control production capacity according to kiln overhauls [26] - The decline in the company's main product revenue in 2025 is mainly due to the decrease in the demand of domestic pharmaceutical enterprises [26] 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Shandong Yaoboh [17] - Industry: Medical devices [17] - Reception time: 2026 - 03 - 23 [17] - Listed company reception personnel: General Manager Zhang Jun, Board Secretary Zhao Haibao, Financial Officer Song Yizhao, Independent Directors Chen Maoxin, Gu Weijun, Sun Zongbin [17] 3.2 Detailed Research Institutions - Institution - related personnel: Investors and others [20] - Reception object type: Investors, others [20] 3.3 Research Institution Proportion - No information provided 3.4 Main Content Data - **Fundraising project progress**: The progress of the fundraising project was 29.26% in the 2024 annual report and 40.20% in 2025, reaching the scheduled use period in December 2026, and it is expected to meet expectations [24] - **Cost - reduction and efficiency - improvement measures**: Please refer to the company's information disclosure announcements [24] - **2026 business plan**: Continue to implement the concept of high - quality, low - cost, and excellent service, stabilize and increase market share, introduce advanced technology and management concepts, accelerate the construction of intelligent factories, and actively cultivate and expand the international market [24] - **"15th Five - Year" strategic concept**: Please refer to the company's information disclosure announcements [24] - **Attitude towards the entry of Sinopharm Group**: Please refer to the disclosed relevant announcements [26] - **Inventory issue**: The inventory increased by 32.61% in 2025. The company will reduce inventory through market expansion and sales increase, and adjust the glass kiln overhaul time to reduce production capacity. Future impairment will have little impact on performance [26] - **Reasons for revenue decline**: The revenue decline is related to the decline of domestic pharmaceutical enterprises and the need to control production capacity according to kiln overhauls [26] - **Reasons for the decline in main product revenue**: The decline in the company's main product revenue in 2025 is mainly due to the decrease in the demand of domestic pharmaceutical enterprises [26]